US2022016032A1PendingUtilityA1

Arc-based capsids and uses thereof

67
Assignee: VNV NEWCO INCPriority: Sep 18, 2018Filed: Oct 8, 2021Published: Jan 20, 2022
Est. expirySep 18, 2038(~12.2 yrs left)· nominal 20-yr term from priority
Inventors:Colin MaloneIan PeikonZachary GilbertAndrey PisarevAdam FraitesJessica Crisp
C07K 14/161C07K 14/16C12N 15/111C07K 14/15A61K 39/0011C07K 14/005C12N 2740/10022A61P 35/00A61K 2039/542A61K 2039/55555A61K 2039/51C12N 2320/32A61K 9/5184A61K 9/127A61K 9/5169A61K 9/1075C07K 2319/00C12N 2310/531A61K 2039/80C12N 2310/141C12N 2310/20C12N 15/85C12N 2310/12A61K 39/39C12N 2310/3519A61K 9/1658C12N 15/907C12N 15/87C12N 15/11C12N 9/22C07K 16/00C07K 14/46C07K 14/435A61K 48/0008A61K 38/00
67
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed herein, in certain embodiments, are recombinant Arc and endogenous Gag polypeptides, and methods of using recombinant Arc and endogenous Gag polypeptides.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition comprising an endogenous Gag (endo-Gag) polypeptide and a nucleic acid molecule that encodes an antigen. 
     
     
         2 . The composition of  claim 1 , wherein the endo-Gag polypeptide assembles into an endo-Gag capsid. 
     
     
         3 . The composition of  claim 1 , wherein the nucleic acid molecule is an mRNA. 
     
     
         4 . The composition of  claim 1 , wherein the nucleic acid molecule comprises a modified base. 
     
     
         5 . The composition of  claim 1 , further comprising a delivery component. 
     
     
         6 . The composition of  claim 5 , wherein the delivery component comprises a liposome or a micelle. 
     
     
         7 . The composition of  claim 5 , wherein the delivery component comprises a microvesicle or a viral envelope. 
     
     
         8 . The composition of  claim 5 , wherein the delivery component comprises a fusogenic molecule. 
     
     
         9 . The composition of  claim 5 , wherein the delivery component comprises a cell-specific binding protein or an engineered protein that binds to an antigen or cell surface molecule. 
     
     
         10 . The composition of  claim 1 , wherein the endo-Gag polypeptide is a Paraneoplastic Ma antigen family polypeptide. 
     
     
         11 . The composition of  claim 1 , wherein the endogenous Gag polypeptide is a retrotransposon Gag-like family polypeptide. 
     
     
         12 . The composition of  claim 11 , wherein the retrotransposon Gag-like family polypeptide is a PEG10 polypeptide. 
     
     
         13 . A method of eliciting an immune response in a subject comprising administering to the subject a composition comprising an endo-Gag polypeptide and a nucleic acid molecule that encodes an antigen. 
     
     
         14 . The method of  claim 13 , wherein the immune response comprises a B cell response. 
     
     
         15 . The method of  claim 13 , wherein the immune response comprises a T cell response. 
     
     
         16 . The method of  claim 15 , wherein the T cell response comprises a CD4+ T cell response, a CD8+ T cell response, a Th1 immune response, a Th2 immune response, a Th17 immune response, a Treg immune response, or a combination thereof. 
     
     
         17 . The method of  claim 13 , wherein the endo-Gag polypeptide is assembled into an endo-Gag capsid. 
     
     
         18 . The method of  claim 13 , wherein the nucleic acid molecule is an mRNA. 
     
     
         19 . The method of  claim 13 , wherein the nucleic acid molecule comprises a modified base. 
     
     
         20 . The method of  claim 13 , wherein the composition further comprises a delivery component. 
     
     
         21 . The method of  claim 20 , wherein the delivery component comprises a liposome or a micelle. 
     
     
         22 . The method of  claim 20 , wherein the delivery component comprises a microvesicle or a viral envelope. 
     
     
         23 . The method of  claim 20 , wherein the delivery component comprises a fusogenic molecule. 
     
     
         24 . The method of  claim 20 , wherein the delivery component comprises a cell-specific binding protein or an engineered protein that binds to an antigen or cell surface molecule. 
     
     
         25 . The method of  claim 24 , wherein the nucleic acid is delivered to a site of interest. 
     
     
         26 . The method of  claim 13 , wherein the endo-Gag polypeptide is a Paraneoplastic Ma antigen family polypeptide. 
     
     
         27 . The method of  claim 13 , wherein the endo-Gag polypeptide is a retrotransposon Gag-like family polypeptide. 
     
     
         28 . The method of  claim 27 , wherein the retrotransposon Gag-like family polypeptide is a PEG10 polypeptide. 
     
     
         29 . The method of  claim 13 , wherein the nucleic acid molecule is delivered to a cell. 
     
     
         30 . The method of  claim 29 , wherein the cell is a muscle cell, a skin cell, a blood cell, or an immune cell.

Join the waitlist — get patent alerts

Track US2022016032A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.